1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
-
  1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
  1. Launch

Gracell Biotechnology Ltd.

Have updates for this profile?  Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Year established

2017

Location

Shanghai China

Primary Industry

Biotechnology

About

Established in 2017 and based in Shanghai, China, Gracell Biotechnology Ltd. operates as a biopharmaceutical company that engages in the discovery and development of cellular therapeutics for patients with hematological malignancy, solid tumor, and degenerative disease.
Current Investors
Lilly Asia Ventures, Suzhou Minying Capital Investment, Frontline BioVentures

Request a demo to show more

Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.gracellbio.com
Company Stage
Mature
Total Amount Raised
Subscriber access only

Deals

Deals Type
LP Direct, Public to Private +1 more
Deal Status Target (s) Deal Date Investor(s) Seller(s) Deal size (Mn) Enterprise value (Mn) Post-money valuation (Mn) EBITDA multiple (x) Revenue multiple (x) Lead partner (s)
Completed Gracell Biotechnology Ltd. 26 Dec 2023
Displaying 1-1 of 1

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.